Buspirone Use for Generalized Anxiety Disorder
Buspirone is FDA-approved for generalized anxiety disorder (GAD) in adults at a dose of 15-30 mg/day, typically divided into 2-3 doses, but it is NOT a first-line agent and should generally be reserved as a second-line option after SSRIs/SNRIs have been tried. 1
FDA-Approved Indication and Dosing
Buspirone is indicated for the management of anxiety disorders or short-term relief of anxiety symptoms, specifically for patients whose diagnosis corresponds to GAD 1. The medication has demonstrated efficacy in controlled trials of outpatients with GAD, including those with coexisting depressive symptoms 1.
Standard Dosing Regimen
- Starting dose: Begin with 7.5 mg twice daily (15 mg/day total)
- Target dose: 15-30 mg/day divided into 2-3 doses
- Titration: Increase by 5 mg/day every 2-3 days as tolerated
- Maximum dose: 60 mg/day (though 30 mg/day is typically sufficient)
Both twice-daily (BID) and three-times-daily (TID) dosing regimens are equally effective 2, 3. A BID regimen (e.g., 15 mg twice daily) may offer better compliance without compromising efficacy or safety 2.
Critical Timing Consideration
A major pitfall with buspirone is the 1-2 week lag time before anxiolytic effects become apparent 4, 5. This differs markedly from benzodiazepines, which work immediately. Patient education about this delay is essential to maintain compliance and prevent premature discontinuation. Psychic symptoms of anxiety improve earlier than somatic symptoms, with measurable improvement typically beginning at week 1-2 and continuing through week 4 4.
Position in Treatment Algorithm
Adults
Buspirone should be considered a second-line agent after SSRIs and SNRIs 6. First-line treatment for adult GAD consists of:
- SSRIs (first-line)
- SNRIs (first-line)
- Buspirone, benzodiazepines, pregabalin, or second-generation antipsychotics (second-line) 6
Pediatric Patients (Ages 6-17)
Buspirone failed to demonstrate efficacy in pediatric GAD trials 1. Two placebo-controlled 6-week trials involving 559 pediatric patients (ages 6-17) showed no significant differences between buspirone (15-60 mg/day) and placebo for GAD symptoms 1. The 2020 AACAP guidelines do not recommend buspirone for pediatric anxiety disorders, instead prioritizing SSRIs, SNRIs, and CBT 7.
Contraindications and Special Populations
Absolute Contraindications
- Severe hepatic or renal impairment: Buspirone is metabolized by the liver and excreted by the kidneys. Patients with severe impairment show increased plasma levels and prolonged half-life, making administration not recommended 1
Pregnancy and Lactation
- Pregnancy Category B: Use only if clearly needed, as adequate human studies are lacking 1
- Nursing mothers: Avoid if clinically possible, as buspirone and metabolites are excreted in rat milk 1
Elderly Patients
No dose adjustment needed based on age alone. Safety and efficacy profiles in 605 elderly patients (mean age 70.8 years) were similar to younger patients 1.
Drug Interactions
Critical CYP3A4 interactions 1:
- Strong CYP3A4 inhibitors (verapamil, diltiazem, erythromycin, itraconazole): Substantially increase buspirone levels—reduce buspirone dose
- Strong CYP3A4 inducers (rifampin): Decrease buspirone levels almost 10-fold—may need dose increase 8
- Food: Increases Cmax and AUC 2-fold; take consistently with or without food 8
Warfarin interaction: One case report of prolonged prothrombin time—monitor INR closely 1
Laboratory Test Interference
Buspirone interferes with urinary metanephrine/catecholamine assays, causing false-positive results for pheochromocytoma 1. Discontinue buspirone at least 48 hours before urine collection for catecholamines.
Adverse Effects
The most common adverse effects are 2, 3:
- Dizziness
- Headache
- Nausea
- Palpitations (more common with BID dosing: 5% vs 1% with TID) 2
Major advantages over benzodiazepines 5:
- No sedation (much less frequent than benzodiazepines)
- No psychomotor or cognitive impairment
- No additive effects with alcohol
- Limited abuse/dependence potential
- No anticonvulsant, hypnotic, or muscle relaxant properties
Duration of Treatment
Efficacy beyond 3-4 weeks has not been systematically demonstrated in controlled trials 1. However, 264 patients were treated for 1 year without ill effects 1. Periodically reassess the need for continued treatment in patients on long-term buspirone.
Key Clinical Pearls
- Start with a subtherapeutic "test dose" to assess tolerability, as initial anxiety/agitation can occur
- Counsel patients extensively about the 1-2 week delay in therapeutic effect to prevent premature discontinuation
- Consider BID dosing for improved compliance
- Buspirone is "anxioselective"—it treats anxiety without sedation, making it useful when daytime alertness is critical
- Not effective for acute anxiety relief; benzodiazepines remain superior for immediate symptom control